University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Clinical Trials

Gastrointestinal Oncology UCSF

Thank you for your interest in GI clinical trials at UCSF.

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.

Please see the links below for current open trials at UC San Francisco.

Colorectal | Early Phase | Gastro Esophageal | Hepatocellular and Biliary Tract
| ImmunotherapyNeuroendocrine | PancreaticOpening Soon | All Cancer Trials at UCSF

COLORECTAL

METASTATIC
 

CC#159510: A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer

Contact: Armand Harb (415)-353-7381: Armand.Harb@ucsf.edu

 

CC#16452: Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu

 

CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)

Contact: Katrina Sadang (415) 476-2958: KatrinaGrace.Sadang@ucsf.edu

 

CC#16706: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms

Contact: Jeremy Burbanks-Ivey (415) 502-4727: Jeremy.Burbanks-Ivey@ucsf.edu

 

NEOADJUVANT RECTAL

Alliance N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu


ANAL
No trials at this time.
 
SURVIVORSHIP
 

CC#164511 Survivor Choices for Eating and Drinking (Succeed) - Colorectal Cancer
Contact: Marissa Savoie (415) 353-7683 SUCCEEDstudy@ucsf.edu
 

CC#154520 Lifestyle and Outcomes after Gastro-Intestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Marissa Savoie (415) 353-7683 LOGICstudy@ucsf.edu

EARLY PHASE

 

CC#15956: A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed against CD47, in Subjects with Advanced Solid and Hematologic Cancers

Contact: Armand Harb (415)-353-7381: Armand.Harb@ucsf.edu

 

CC# 159518: A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer

Contact: Nilson Wu (415) 353-4084: Nilson.Wu@ucsf.edu

 

AMC095: A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

             Contact: Denisha Otis (415) 748-9513: Denisha.Otis@ucsf.edu

 

CC#159516: A phase 1b, Open-Label Study of Alpelisib (BYL719) in Combination with Cisplatin in Patients with HPV+ Solid Tumor Malignancies

Contact: Armand Harb (415)-353-7381: Armand.Harb@ucsf.edu

CC#16954: Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors.

Contact: Denisha Otis (415) 748-9513: Denisha.Otis@ucsf.edu

 

CC159520: A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Contact: Claire Hooker (415) 885-3724 : Claire.Hooker@ucsf.edu

 

CC#16955: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-like Protein 3-Expressing Advanced Solid Tumors

Contact: Emily Boyd (415)-514-6638: Emily.Boyd2@ucsf.edu

 

CC#169514: A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations

Contact: Ann Chan (415) 885-3670: Ann.Chan@ucsf.edu

 

CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer

Contact: Phu Lam (415) 514-6363: Phu.Lam@ucsf.edu

 

CC#169518: Phase 1 Clinical Trial of VX-970 in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors

Contact: Phu Lam (415) 514-6363: Phu.Lam@ucsf.edu

 

CC#169519: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (only SCLC and TNBC)

Contact: Kathleen (Katie) Comerford (415) 514-6674: Kathleen.Comerford@ucsf.edu

 

CC#17951: A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1 or ALK Molecular Alterations

Contact: Claire Hooker (415) 885-3724: Claire.Hooker@ucsf.edu

GASTRO ESOPHAGEAL

CC#16459: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

Contact Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu

 

CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Contact: Christopher Wong (415) 476-1044: Christopher.Wong@ucsf.edu
 

  

HEPATOCELLULAR AND BILIARY TRACT 

 

CC#133526: A Pilot Study of PET/MRI Localization of Ytrrium-90 Microspheres Following Hepatic Radioembolization in Patients with Liver Malignancies

Contact: Curt Johanson (415) 353-2310: Curt.Johanson@ucsf.edu

 

CC#16451: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremeliumumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

Contact: Trang Nguyen (415) 353-9544: TrangX.Nguyen@ucsf.edu

 

CC#154524: A Phase II Trial of Pembrolizumab (MK-3475) with GM-CSF Induction in Advanced Biliary Cancers

Contact: Emily Mitchell (415) 476-5442: Emily.Mitchell@ucsf.edu

 

CC#16458 : A Multicenter Phase I/II Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

Contact: Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu

 

CC#164514: Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization in Hepatocellular Carcinoma

Contact: Curt Johanson (415) 353-2310: Curt.Johanson@ucsf.edu

 

CC#16708: A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)

Contact: Jeremy Burbanks-Ivey (415) 502-4727: Jeremy.Burbanks-Ivey@ucsf.edu

 

CC#17451: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

Contact: Malori Mindo (415) 502-6313: Malori.Mindo@ucsf.edu

 

CC#17457: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu

IMMUNOTHERAPY

CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)

Contact: Katrina Sadang (415) 476-2958: KatrinaGrace.Sadang@ucsf.edu

 

CC#16706: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms

Contact: Jeremy Burbanks-Ivey (415) 502-4727: Jeremy.Burbanks-Ivey@ucsf.edu

 

CC#16708: A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)

Contact: Jeremy Burbanks-Ivey (415) 502-4727: Jeremy.Burbanks-Ivey@ucsf.edu

 

CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)

Contact: Katrina Sadang (415) 476-2958: KatrinaGrace.Sadang@ucsf.edu

 

CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Contact: Christopher Wong (415) 476-1044: Christopher.Wong@ucsf.edu

 

CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu

NEUROENDOCRINE TUMORS

 

CC#149511: A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors

Contact:  Kathleen (Katie) Comerford (415) 514-6674: Kathleen.Comerford@ucsf.edu

 

CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Contact: Claire Hooker (415)-885-3724: Claire.Hooker@ucsf.edu

 

CC#16455: Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients with Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy

Contact: Bryant Chee (415) 353-7145: Bryant.Chee@ucsf.edu

 

CC#17455: Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Contact: Bryant Chee (415) 353-7145: Bryant.Chee@ucsf.edu

 

CC#17459: Phase II Randomized Embolization Trial for Neuroendocrine Tumor Metastases To The Liver (RETNET) 

Contact: Curt Johanson (415) 353-2310: Curt.Johanson@ucsf.edu

PANCREATIC

 

 

CC#144515: A Phase II Study of PEGPH20, Gemcitabine Plus Nab-Paclitaxel in Patients With Upfront or Borderline Resectable Pancreatic Cancer

Contact:  Louis Wong (415) 514-8101: Louis.Wong@ucsf.edu

  

CC#164518: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Contact:  Louis Wong (415) 514-8101: Louis.Wong@ucsf.edu

 

CC#16706: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms

Contact: Jeremy Burbanks-Ivey (415) 502-4727: Jeremy.Burbanks-Ivey@ucsf.edu

 

CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu

 

 

 

************************************************** 

**TO BE OPENED WITHIN 3 MONTHS**

CC#169521: Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair (Note: restricted to patients with defects in the following molecules: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)

Contact: Armand Harb (415) 353-7381: Armand.Harb@ucsf.edu

 

CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy For Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases

Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu

 

CC#174512: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer) 

Contact: Shohei Burns (415) 514-6258: Shohei.Burns@ucsf.edu

 

CC#174517: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

Contact: Julia Whitman (415) 353-7683: Julia.Whitman@ucsf.edu

 

CC#174522: A Phase 1b and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination with PLX3397 or Sunitinib in Patients with Advanced Solid Tumors and Patients with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated with Imatinib Mesylate/KIT Directed Tyrosine Kinase Inhibitor (TKI) Therapy

Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu

 

CC#174528: A study of Nivolumab in Combination With Trametinib or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers

Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu

 


For information on Early Phase clinical trials not listed please contact:

Kamran Abri Lavasani (415) 514-6245: Kamran.AbriLavasani@ucsf.edu

 

For information on Immunotherapy trials not listed please contactAndrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu